We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Consortium for Analytic Standardization in Immunohistochemistry (IHC) Launched to Improve Patient IHC Test Accuracy

By LabMedica International staff writers
Posted on 11 Mar 2022
Print article
Image: IHC staining controls (Photo courtesy of Boston Cell Standards)
Image: IHC staining controls (Photo courtesy of Boston Cell Standards)

Standard patient blood tests can be analyzed in any lab and yield the same results every time because of international reference standards that ensure all tests are aligned with one another; both patient and physician can have confidence in the results wherever the tests are performed. No such reference standards exist in immunohistochemistry (IHC), meaning that different labs could – and often do – return different results from the same sample. Now, a newly-launched organization, the Consortium for Analytic Standardization in Immunohistochemistry (CASI), aims to improve patient IHC test accuracy and reproducibility.

CASI, launched by Boston Cell Standards (Boston, MA, USA), is led by an international panel of pathologists and scientists, with a mission to integrate analytic reference standards into IHC, a test format widely used in surgical pathology to evaluate cancers in tissue samples and determine correct treatment. Boston Cell Standards has invented the first and only IHC reference materials, including calibrators for IHC standardization and controls for daily verification of IHC assay accuracy. These tools incorporate concentration measures that are traceable to a National Institute of Standards and Technology (NIST) standard.

Rates of clinically inadequate IHC testing are roughly 10 times that of clinical blood testing labs, with test discrepancy rates of 10% to 30%. Introducing reference standards will raise the quality of IHC testing by giving pathologists certainty that their results are accurate and oncologists greater confidence in patient diagnosis and treatment selection. CASI will conduct studies to determine appropriate analytic sensitivity thresholds for selected IHC tests, publish the data it collects, and then offer analytic sensitivity recommendations. In addition to guiding routine clinical practice, these recommendations will be intended to facilitate and simplify methodology transfer between laboratories, from published literature, and in clinical trials.

“Biopsy testing in the pathology lab with immunohistochemistry is essential to characterizing a patient’s cancer and determining the proper course of treatment. However, a lack of industry-wide standards, calibrators and controls, and traceable units of measure has, for years, frustrated attempts to lower the error rate. It holds the entire field of pathology back,” said Dr. Steve Bogen, CEO of Boston Cell Standards, a board-certified clinical pathologist. “Building analytic standards and integrating them into routine clinical practice and clinical research will provide pathologists and clinical research scientists vital tools to inform their best work.”

“Harmonization among all IHC laboratories is an essential goal for improved patient care. The ability to set objective, quantitative lower limits of detection for any assay is a much-needed step in this direction,” said Dr. Emina Torlakovic, a board-certified anatomic and clinical pathologist and hematopathologist; director of Canadian Biomarker Quality Assurance academic program; division head of Hematopathology, Dept. of Pathology & Laboratory Medicine, Saskatchewan Health Authority and University of Saskatchewan; and, chairperson of the CASI steering committee. “The consortium’s work stands to make a valuable and lasting positive impact on labs, clinicians and patients, and improve the delivery of care. I’m honored to be a part of it.”

Related Links:
Boston Cell Standards 

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
Chemiluminescence Analyzer
DZ-Lite 3000 Plus
3-DIFF Hematology Analyzer
3-Part Diff Hematology Analyzer

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.